Aim:The aim of this pilot study was to evaluate the therapeutic and safety performance of an intramuscular treatment protocol of multidose of allogeneic adipose stem cells (ASCs) isolated, characterized, and expanded ex vivo from a healthy canine donor. Materials and Methods:Twelve dogs diagnosed with canine atopic dermatitis (CAD) were intramuscularly treated with 0.5×10 6 of cryopreserved ASCs from a healthy immunized young canine Ehrlichia canis free donor weekly for 6 weeks. Treatment efficacy was evaluated by the pruritus index and the CAD Lesion Index (CADLI) test. Safety and adverse effects were determined by injection site reaction, weight, blood chemistry, liver function, and whole blood count.Results: Canine ASCs obtained from a donor met the minimum qualities required for this type of cells and showed viability of 90% after thawing. The efficacy of the CADLI score and the pruritus index in 12 dogs with atopic dermatitis was statistically significant efficacy. No adverse reactions were observed at the intramuscular application site, or in relation to animal weight, blood cell populations, or liver and renal function. Conclusion:These results suggest that intramuscular administration of cryopreserved ASCs to dogs with atopic dermatitis is a promising cellular therapeutic product for the relief of the symptoms of this disease; however, the duration of the effects obtained with this dose and with other doses should be evaluated, as well as possible immune reactions. As far as we know, this is the first report of the use of multiple intramuscular doses cryopreserved ASCs to treat atopic dermatitis.

No abstract

Biological characteristics of a subpopulation of cancer stem cells from two triple-negative breast tumour cell lines, HELIYON,

RESUMEN:En la enfermedad hepática crónica el trasplante ortotópico es la única alternativa terapéutica actual pero es limitada por falta de donantes. Ensayos con células madre adultas en daño hepático agudo evidencian promisorios resultados. El objetivo de este trabajo fue evaluar en ratas con daño hepático crónico la efectividad de la infusión de células madre adiposas humanas (CMAd-h). Ratas con fibrosis hepática inducida por tioacetamida fueron agrupadas en: grupo I control que no recibió tioacetamida ni células madre, grupo II recibió tioacetamida y suero fisiológico i.v., grupo III recibió tioacetamida y células madre adiposas 1 x 10 6 /kg i.v. vía vena de la cola. La regeneración hepática histológica se evaluó por el index METAVIR, mientras las Macrophagocytus stellatus, células estrelladas a-SMA+ y células colágeno I+ por inmunohistoquímica; el daño funcional se evaluó por los niveles sanguíneos de los analitos Aspartato Aminotransferasa (AST), Alanina Aminotransferasa (ALT), Fosfatasa Alcalina (ALP), úrea y nitrógeno ureico (BUN) y hemograma. Los resultados muestran atenuación del daño estructural hepático evidenciado por disminución de los nódulos, del grado de lesión histológica en el score Metavir, y disminución de Macrophagocytus stellatus, células a-SMA+ y células colágeno tipo I+; funcionalmente hay reducción moderada de AST, ALT, urea, BUN y disminución moderada de células blancas pero efecto favorable sobre el volumen corpuscular media y la hemoglobina corpuscular media. Ocho semanas después de la infusión hay escasa población de CMAd-h en el hígado. En conclusión la infusión intravenosa de CMAd-h en ratas disminuye el daño funcional y estructural de la fibrosis hepática con escasa persistencia de CMAd-h en el parénquima hepático. A nuestro conocimiento este es el primer trabajo que evalúa el efecto de las CMAd-h en el modelo daño hepático crónico murino y la persistencia de las células trasplantadas.

Background: Buddleja incana Ruiz & Pav. (Scrophulariaceae) is an ancestral medicinal plant from the South American Andes used in traditional medicine since the Inca culture, but little studied in its chemical components at present. The aim of this review is to gather all the scientific information about this plant in order to use it in alternative medicine and at the same time to stimulate its study in research groups in the Andean countries.Materials and methods: Several electronic search engines and specialized reference tools were used, such as Google, Google Scholar, Scopus, Web of Science, publication sites and electronic databases (Pubmed, Springer, Wiley and Science Direct).Results: Phytochemical studies have found the following chemical components:flavonoids, steroids, saponins, leukoanthocyanidins, triterpenes, phenols, tannins, reducing sugars, coumarins, alkaloids, terpenes and verbascosides. This plant is used to treat several diseases and pathological conditions, having demonstrated anti-inflammatory, antineoplastic, antispasmodic, antibacterial, antifungal and febrifuge effects, in the following conditions. wounds, neuralgias, cutaneous and gastrointestinal ulcers, papillomatosis, skin cancer, photosensitization, immunomodulator.Conclusions: Buddleja incana was a sacred and medicinal plant of the Incas. Nowadays it is used for the treatment of hepatic, bronchial and urogenital diseases. It has diuretic, anti-inflammatory, analgesic, antirheumatic, antimicrobial, antihyperglycemic, wound regenerating effects, for the treatment of warts, skin ulcers, antiproliferative, and for its photoprotective effect on the skin. In veterinary medicine it is used to treat skin photosensitization in sheep, in bovine warts and in oral canine papillomatosis.